Skip to main content
OpenTrials
Completed

NCT Number: NCT04906941

Assessment of the Impact of Gadolinium Injection on the Measurement of the QSM Signal

Patients meeting the inclusion and non-inclusion criteria will be offered to participate in the study. If they agree, they will perform an MRI without injection to obtain the QSM then perform the MRI with injection that was prescribed to them as part of the care, then they will perform a second time the MRI without injection to obtain the QSM. They will also answer a short questionnaire documenting their previous exposure to gadolinium.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

White Matter Disease Brain Diseases Central Nervous System Diseases Leukoencephalopathies Nervous System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hhopital fondation adolphe de rothschild

Paris, 75019, France

About this study

Patients meeting the inclusion and non-inclusion criteria will be offered to participate in the study. If they agree, they will perform an MRI without injection to obtain the QSM then perform the MRI with injection that was prescribed to them as part of the care, then they will perform a second time the MRI without injection to obtain the QSM. They will also answer a short questionnaire documenting their previous exposure to gadolinium.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients over 18 years old
  • with an inflammatory CNS pathology
  • to benefit as part of care from an MRI with injection of gadolinium
  • consent to participate in the study
  • beneficiary of a social protection scheme

Exclusion criteria

  • pregnant or breastfeeding woman
  • patient benefiting from a legal protection measure
  • Patient having performed more than 3 MRI exams with gadolinium injection during his life

Secondary exclusion criteria :

  • motion artifact not allowing image interpretation
  • patient who has not completed one of the following sequences: T1 anatomical, FLAIR, or QSM pre-gadolinium injection.

Secondarily excluded patients will be replaced up to a maximum of 25 patients.

Treatment and study plan

MRI

Device

SWI QSM 1.0iso 8 echos sequence performed before and after the injected MRI prescribed as part of the treatment.

  • Sense 2 * 2: 9min33s

Primary outcomes

  1. mean of the delta observed between the QSM of the white matter before and after injection of gadolinium

    Time frame: 1 DAY

    mean of the delta observed between the QSM of the white matter before and after injection of gadolinium

Sponsors and collaborators

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Network

Registry information

Acronym: GADO-QSM

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
May 28, 2021
Registry last updated
Jan 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.